Dossier assessment
Risankizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Risankizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Risankizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with active psoriatic arthritis who have had an inadequate response or who have been intolerant to a prior therapy with disease-modifying antirheumatic drugs (DMARDs)
- Adults with active psoriatic arthritis who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy: added benefit not proven.
- Adults with active psoriatic arthritis who have had an inadequate response or who have been intolerant to a prior therapy with biologic disease-modifying antirheumatic drugs (bDMARDs): added benefit not proven.
Project details
- Project no.
- A21-156
- Commission
- Commission awarded on 01.12.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Skin and hair
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Risankizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Risankizumab (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Risankizumab (Crohn’s disease) - Benefit assessment according to § 35a SGB V
Status: Commission completed